Harbor Capital Advisors, Inc. Allogene Therapeutics, Inc. Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.92 - $5.63 $68,114 - $131,331	23,327 Added 31.73%	96,837 $433,000
Q4 2023 Jan 08, 2024	BUY	$2.28 - $3.5 $11,379 - $17,468	4,991 Added 7.28%	73,510 $235,000
Q3 2023 Oct 20, 2023	BUY	$3.17 - $5.96 $33,199 - $62,419	10,473 Added 18.04%	68,519 $217,000
Q2 2023 Jul 11, 2023	BUY	$4.53 - $6.74 $23,954 - $35,641	5,288 Added 10.02%	58,046 $288,000
Q1 2023 Apr 26, 2023	BUY	$4.92 - $8.21 $53,908 - $89,956	10,957 Added 26.21%	52,758 $260,000
Q4 2022 Jan 20, 2023	SELL	$5.62 - $11.11 $109,550 - $216,567	-19,493 Reduced 31.8%	41,801 $0
Q3 2022 Oct 28, 2022	SELL	$10.32 - $17.28 $296,163 - $495,901	-28,698 Reduced 31.89%	61,294 $662,000
Q2 2022 Jul 26, 2022	SELL	$6.78 - $12.28 $18,733 - $33,929	-2,763 Reduced 2.98%	89,992 $1.03 Million
Q1 2022 Apr 28, 2022	SELL	$7.65 - $15.29 $204,958 - $409,649	-26,792 Reduced 22.41%	92,755 $845,000
Q4 2021 Feb 04, 2022	BUY	$13.13 - $24.52 $1.57 Million - $2.93 Million	119,547 New	119,547 $1.78 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.